Literature DB >> 8643566

Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 signaling.

K S Ravichandran1, V Igras, S E Shoelson, S W Fesik, S J Burakoff.   

Abstract

Stimulation via the T-cell growth factor interleukin 2 (IL-2) leads to tyrosine phosphorylation of Shc, the interaction of Shc with Grb2, and the Ras GTP/GDP exchange factor, mSOS. Shc also coprecipitates with the IL-2 receptor (IL-2R), and therefore, may link IL-2R to Ras activation. We have further characterized the Shc-IL-2R interaction and have made the following observations. (i) Among the two phosphotyrosine-interaction domains present in Shc, the phosphotyrosine-binding (PTB) domain, rather than its SH2 domain, interacts with the tyrosine-phosphorylated IL-2R beta chain. Moreover, the Shc-PTB domain binds a phosphopeptide derived from the IL-2R beta chain (corresponding to residues surrounding Y338, SCFTNQGpYFF) with high affinity. (ii) In vivo, mutant IL-2R beta chains lacking the acidic region of IL-2Rbeta (which contains Y338) fail to phosphorylate Shc. Furthermore, when wild type or mutant Shc proteins that lack the PTB domain were expressed in the IL-2-dependent CTLL-20 cell line, an intact Shc-PTB domain was required for Shc phosphorylation by the IL-2R, which provides further support for a Shc-PTB-IL-2R interaction in vivo. (iii) PTB and SH2 domains of Shc associate with different proteins in IL-2- and T-cell-receptor-stimulated lysates, suggesting that Shc, through the concurrent use of its two different phosphotyrosine-binding domains, could assemble multiple protein complexes. Taken together, our in vivo and in vitro observations suggest that the PTB domain of Shc interacts with Y338 of the IL-2R and provide evidence for a functional role for the Shc-PTB domain in IL-2 signaling.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8643566      PMCID: PMC39235          DOI: 10.1073/pnas.93.11.5275

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  GRB2 and phospholipase C-gamma 1 associate with a 36- to 38-kilodalton phosphotyrosine protein after T-cell receptor stimulation.

Authors:  M Sieh; A Batzer; J Schlessinger; A Weiss
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

2.  A complex of Grb2 adaptor protein, Sos exchange factor, and a 36-kDa membrane-bound tyrosine phosphoprotein is implicated in ras activation in T cells.

Authors:  L Buday; S E Egan; P Rodriguez Viciana; D A Cantrell; J Downward
Journal:  J Biol Chem       Date:  1994-03-25       Impact factor: 5.157

3.  B cell antigen receptor cross-linking induces phosphorylation of the p21ras oncoprotein activators SHC and mSOS1 as well as assembly of complexes containing SHC, GRB-2, mSOS1, and a 145-kDa tyrosine-phosphorylated protein.

Authors:  T M Saxton; I van Oostveen; D Bowtell; R Aebersold; M R Gold
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

4.  The adapter protein Shc interacts with the interleukin-2 (IL-2) receptor upon IL-2 stimulation.

Authors:  K S Ravichandran; S J Burakoff
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

5.  Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling.

Authors:  Y Nakamura; S M Russell; S A Mess; M Friedmann; M Erdos; C Francois; Y Jacques; S Adelstein; W J Leonard
Journal:  Nature       Date:  1994-05-26       Impact factor: 49.962

6.  Direct interaction between Shc and the platelet-derived growth factor beta-receptor.

Authors:  K Yokote; S Mori; K Hansen; J McGlade; T Pawson; C H Heldin; L Claesson-Welsh
Journal:  J Biol Chem       Date:  1994-05-27       Impact factor: 5.157

7.  Activation of a tyrosine protein kinase is an early event in the stimulation of T lymphocytes by interleukin-2.

Authors:  E M Saltzman; R R Thom; J E Casnellie
Journal:  J Biol Chem       Date:  1988-05-25       Impact factor: 5.157

8.  Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav.

Authors:  Z Songyang; S E Shoelson; J McGlade; P Olivier; T Pawson; X R Bustelo; M Barbacid; H Sabe; H Hanafusa; T Yi
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

9.  Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation.

Authors:  B H Nelson; J D Lord; P D Greenberg
Journal:  Nature       Date:  1994-05-26       Impact factor: 49.962

10.  Evidence for differential intracellular signaling via CD4 and CD8 molecules.

Authors:  K S Ravichandran; S J Burakoff
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  22 in total

1.  Evidence for a requirement for both phospholipid and phosphotyrosine binding via the Shc phosphotyrosine-binding domain in vivo.

Authors:  K S Ravichandran; M M Zhou; J C Pratt; J E Harlan; S F Walk; S W Fesik; S J Burakoff
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Hyperglycemia-induced p66shc inhibits insulin-like growth factor I-dependent cell survival via impairment of Src kinase-mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells.

Authors:  Gang Xi; Xinchun Shen; Yashwanth Radhakrishnan; Laura Maile; David Clemmons
Journal:  Endocrinology       Date:  2010-06-09       Impact factor: 4.736

3.  Sequence-specific recognition of the internalization motif of the Alzheimer's amyloid precursor protein by the X11 PTB domain.

Authors:  Z Zhang; C H Lee; V Mandiyan; J P Borg; B Margolis; J Schlessinger; J Kuriyan
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

4.  Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation.

Authors:  Y J Zhou; K S Magnuson; T P Cheng; M Gadina; D M Frucht; J Galon; F Candotti; R L Geahlen; P S Changelian; J J O'Shea
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

5.  TCR-mediated Erk activation does not depend on Sos and Grb2 in peripheral human T cells.

Authors:  Nicole Warnecke; Mateusz Poltorak; Bhavani S Kowtharapu; Boerge Arndt; James C Stone; Burkhart Schraven; Luca Simeoni
Journal:  EMBO Rep       Date:  2012-04       Impact factor: 8.807

6.  Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor gamma(c) chain for Janus kinase activation leading to T cell proliferation.

Authors:  B H Nelson; B C McIntosh; L L Rosencrans; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

7.  Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Authors:  Michal Marzec; Krzysztof Halasa; Xiaobin Liu; Hong Y Wang; Mangeng Cheng; Donald Baldwin; John W Tobias; Stephen J Schuster; Anders Woetmann; Qian Zhang; Suzanne D Turner; Niels Ødum; Mariusz A Wasik
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

8.  Functional dissection of the cytoplasmic subregions of the IL-2 receptor betac chain in primary lymphocyte populations.

Authors:  H Fujii; K Ogasawara; H Otsuka; M Suzuki; K Yamamura; T Yokochi; T Miyazaki; H Suzuki; T W Mak; S Taki; T Taniguchi
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

9.  p66shc negatively regulates insulin-like growth factor I signal transduction via inhibition of p52shc binding to Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 leading to impaired growth factor receptor-bound protein-2 membrane recruitment.

Authors:  Gang Xi; Xinchun Shen; David R Clemmons
Journal:  Mol Endocrinol       Date:  2008-07-07

10.  Evidence of STAT5-dependent and -independent routes to CD8 memory formation and a preferential role for IL-7 over IL-15 in STAT5 activation.

Authors:  Roslyn A Kemp; Claire F Pearson; Georgina H Cornish; Benedict P Seddon
Journal:  Immunol Cell Biol       Date:  2009-12-01       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.